Sign In
Buy LLY
$1,125.38
+42.15 (+3.89%)
At Close: Jun 04, 2026
CVS drops Lilly's Zepbound
02:53pm, Tuesday, 01'st Jul 2025
CNBC's Angelica Peebles reports on news regarding CVS.
Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock
10:01am, Tuesday, 01'st Jul 2025
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
Which Stock Will Dominate the Weight Management Market Through 2030?
06:47am, Saturday, 28'th Jun 2025
The market for weight management medicines has been the hottest therapeutic area in the past two years. Plenty of companies are now trying to make waves in this space.
NVO vs. LLY: Which Obesity Powerhouse is the Stronger Bet Now?
12:11pm, Friday, 27'th Jun 2025
Eli Lilly edges ahead of Novo Nordisk as the stronger obesity bet, backed by robust sales growth, pipeline depth and strategic momentum.
Can LLY's Next-Generation Obesity Pipeline Fuel Further Growth?
10:45am, Thursday, 26'th Jun 2025
Eli Lilly bets on next-generation obesity candidates like orforglipron and retatrutide to sustain growth amid rising competition.
Eli Lilly seen as the stronger bet amid escalating competition with Novo in India
06:25am, Thursday, 26'th Jun 2025
The global fight between Eli Lilly and Novo Nordisk for dominance in the red-hot weight-loss drug market is shifting to India, one of the fastest-growing pharmaceutical frontiers. As rising obesity an
Lilly to launch Mounjaro pen in India to compete with Novo's Wegovy
03:45am, Thursday, 26'th Jun 2025
Eli Lilly said on Thursday India's drug regulator had approved the launch of pre-filled injector pens of its blockbuster weight-loss drug, Mounjaro, giving it more options to compete with Novo Nordisk
Buy Eli Lilly While The Market Hesitates And Let Time Make You Dominate
11:08pm, Wednesday, 25'th Jun 2025
Eli Lilly is positioned for a 30-50% return in the next 12 months based on a nexus of value and growth. While others hesitate on greatness, I buy at the prices everyone else wishes they did. Risks are
Weight loss and diabetes jabs linked to potentially fatal side effect
10:39pm, Wednesday, 25'th Jun 2025
Weight loss and diabetes jabs taken by more than a million people in the UK have been linked to a potential serious side effect, with some deaths, according to data from the UK medicines regulator.
Healthy Returns: New weight loss drug data show Eli Lilly is gaining ground
01:33pm, Wednesday, 25'th Jun 2025
Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge announces a $300 million funding round.
3 Reasons to Buy Eli Lilly Stock Like There's No Tomorrow
06:05am, Wednesday, 25'th Jun 2025
Eli Lilly (LLY 1.12%) has been on fire over the past two years. The drugmaker has generated excellent financial results and delivered strong market performance -- so strong that detractors might think
2 Dividend Aristocrats Bargains To Buy And 'Never Let Go'
08:00am, Tuesday, 24'th Jun 2025
Buying Dividend Aristocrats at bargain prices can be a winning investment strategy. I highlight two such names that are undervalued compared to historical norms while paying strong and well-covered di
Eli Lilly: It Is A Bet On Human Longevity
12:05am, Tuesday, 24'th Jun 2025
Eli Lilly's recent stock dip creates a compelling buying opportunity, with its valuation multiples falling to 2022 levels, despite explosive growth prospects and a deep, innovative product pipeline. D
Eli Lilly (LLY) Surpasses Market Returns: Some Facts Worth Knowing
06:46pm, Monday, 23'rd Jun 2025
The latest trading day saw Eli Lilly (LLY) settling at $770.64, representing a +1.04% change from its previous close.
Pharma companies need to beef up M&A right now, says Mizuho's Jared Holz
06:10pm, Monday, 23'rd Jun 2025
Jared Holxz, Mizuho, joins 'Fast Money' to talk competition in the obesity drug space.
